Amryt Pharma
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Amryt Pharma sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Amryt Pharma: 4 sponsored US clinical trials, 3 recruiting.
Amryt Pharma sponsors 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting. 2 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Partial Lipodystrophy, with 2 trials.
Upper-quartile sponsor footprint
Amryt Pharma sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
NCT06679270
MEASuRE: Metreleptin Effectiveness And Safety Registry
NCT02325674
LOWER: Lomitapide Observational Worldwide Evaluation Registry
NCT02135705
Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL
NCT05164341
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 2 |
Therapeutic Areas
Where Amryt Pharma enrollment is open (later-stage tilt)
3 recruiting of 4 indexed (75% open).
Phase mix: 2 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Partial Lipodystrophy (2 trials), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Amryt Pharma: open-pipeline peers nationwide
Peers matched on 4 registered trials and 75% open enrollment, not the therapeutic-area sidebar.
Amryt Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 75% open enrollment (± trial volume)
- Acepodia Biotech · 75% recruiting · 4 trials
- American Laboratory Products Company · 75% recruiting · 4 trials
- Amydis · 75% recruiting · 4 trials
- BioLab Holdings · 75% recruiting · 4 trials
Related
What to do with this Amryt Pharma page
4 registered trials is a research-attention snapshot, not an endorsement of Amryt Pharma or any single study.
- 3 of Amryt Pharma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Partial Lipodystrophy is the condition Amryt Pharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Partial Lipodystrophy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Amryt Pharma pipeline card: 4 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.